Ny teknologi för studier av proteinfosforylering

Epiquant är en ny plattform för analys av cellsignalering.

Finding your way at the fairs

For details on exhibitors, booths, seminars and the fair map we have gathered the important sites for you.

How to get the most out of the fair

Ingen effekt av astmamedicin

En klinisk studie visar att Astrazenecas läkemedel UDB inte minskar astmasymptom.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Lytix calls in cash

Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.

New map of eye proteins

A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.